

Award Number: DAMD17-00-1-0452

TITLE: Role of c-myb in Breast Development and Cancer

PRINCIPAL INVESTIGATOR: Yen Lieu
Premkumar E. Reddy, Ph.D.

CONTRACTING ORGANIZATION: Temple University School of Medicine
Philadelphia, Pennsylvania 19140

REPORT DATE: June 2003

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20031003 068

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2003	3. REPORT TYPE AND DATES COVERED Annual Summary (15 May 00 - 14 May 03)	
4. TITLE AND SUBTITLE Role of c-myb in Breast Development and Cancer			5. FUNDING NUMBERS DAMD17-00-1-0452	
6. AUTHOR(S) Yen Lieu Premkumar E. Reddy, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Temple University School of Medicine Philadelphia, Pennsylvania 19140 E-Mail: yenklieu@hotmail.com			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) c-myb, along with A-myb and B-myb, belongs to the myb gene family which codes for nuclear proteins that bind DNA in a sequence-specific manner and function as regulators of transcription. There is a large body of evidence to suggest a role for c-myb in breast development and cancer. c-myb is highly expressed in all estrogen receptor positive (ER+) breast tumors as well as ER+ mammary carcinoma cell lines. In addition, our <i>in situ</i> hybridization studies show that c-myb is expressed at high levels in ductal cells from breast tissues of virgin and pregnant mice. To address the role of c-myb in mammary development and cancer, we have created c-myb conditional knockout mice where the expression of this gene is interrupted specifically in the mammary gland using the Cre-lox system. To date, we have generated two female mice that are homozygous for the c-myb floxed alleles (conditional deletion alleles), and additionally, one of the two female mice bears the WAP-cre transgene while the other carries the MMTV-cre transgene. The generation of these breast-specific c-myb conditional knockout mice will afford us the opportunity to dissect the role of c-myb in normal breast development and cancer.				
14. SUBJECT TERMS c-myb, estrogen receptor, breast cancer, ductal proliferation			15. NUMBER OF PAGES 8	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	7
References.....	8
Appendices.....	

Introduction

The development of breast cancer is a multistage process involving alterations in tumor suppressor genes and oncogenes. Overexpression of c-myc oncogene has been reported in human estrogen receptor positive (ER+) tumors and ER+ mammary carcinoma cell lines (1,2,3, also our unpublished data). In fact, cumulative data have shown c-myc to be one of the most frequently altered genes in breast cancer (1,4,5). In addition, recent data have shown a correlation between c-myc oncogene amplification and hereditary BRCA1 breast cancer (6). c-myc, along with A-myc and B-myc, belongs to the myc gene family which codes for nuclear proteins that bind DNA in a sequence-specific manner and function as regulators of transcription (7,8).

c-myc is predominantly expressed in hematopoietic cells and its essential role for the proliferative potential of these cells has been well established (9). Homozygous null c-myc mutant mice die in utero due to defects in fetal hepatic hematopoiesis (10). However, the role of c-myc in breast development and breast cancer is beginning to emerge only recently. The first evidence that implicated a role for c-myc in breast tumors came from the observation that this gene is highly expressed in all estrogen receptor positive (ER+) breast tumors and mammary carcinoma cell lines (1,2,3, also our unpublished data). In addition, expression of a dominant negative mutant of the c-myc in ER+ breast carcinomas was found to result in their growth arrest and loss of tumorigenicity (our unpublished observations). To determine whether c-myc gene plays a role in breast development, we examined the pattern of expression of this gene in breast tissues derived from virgin, pregnant and lactating mice. *In situ* hybridization studies show that c-myc is expressed at high levels in ductal cells derived from breast tissues of virgin and pregnant mice but is down-regulated in breast tissue of lactating mice. This observation combined with the observation that c-myc is highly expressed in ER+ breast tumor cells suggests that this gene might play a critical role in estrogen-mediated ductal cell proliferation.

Body

The main objective of my application is to study the effects of c-myc gene deletion on breast development by generating c-myc conditional knockout mice where the c-myc gene is deleted specifically in mammary gland using the embryonic stem (ES) cell technology and the Cre-lox system.

During the grant years 2000 to 2003, I had generated 4 karyotypically normal recombinant c-myc ES cell clones (R1/51, R1/62, R1/161 and RW4/23) from R1 ES and RW4 ES parental cells and our modified conditional c-myc targeting vector. From three of these recombinant clones, I was able to generate 7 karyotypically normal type II conditional c-myc deletion ES clones (R1/51.29/5, R1/51.18/57, R1/51.18/82, R1/161/91, RW4/23/47, RW4/23/62 and RW4/23/128). Three out of four type II conditional c-myc deletion ES cell clones (R1/51.29/5, R1/51.18/82, R1/161/91 but not RW4/23/47) that were sent out for microinjection into blastocysts, produced chimeras. Only chimeras obtained from R1/51.18/82 and R1/161/91 type II conditional c-myc deletion ES cell clones, produced c-myc^{F/wt} (F=floxed, wt=wild-type)

heterozygotes-gone germline. When I crossed the $c\text{-myb}^{F/wt}$ heterozygotes, I was able to obtain some homozygotes, $c\text{-myb}^{F/F}$, indicating that there were no splicing interference from the loxP's, flanking the $c\text{-myb}$ region I want to delete.

To obtain breast-specific $c\text{-myb}$ knockout mice, I crossed the $c\text{-myb}^{F/wt}$ heterozygotes with MMTV-cre mice to obtain F1 mice. I crossed the F1 mice ($c\text{-myb}^{F/wt}/\text{MMTVcre}+$ or $c\text{-myb}^{F/wt}/\text{MMTVcre}-$) with each other to obtain F2 breast-specific knockout mice ($c\text{-myb}^{F/F}/\text{MMTVcre}+$). However, after 4 F2-litters and 34 mice, I did not obtain any $c\text{-myb}^{F/F}/\text{MMTVcre}+$ mice nor $c\text{-myb}^{F/F}/\text{MMTVcre}-$ mice. Since there may be leakiness into the hematopoietic compartment associated with the MMTV promoter (11) and $c\text{-myb}$ is critical for fetal hematopoiesis (10), presumably, these $c\text{-myb}^{F/F}/\text{MMTVcre}+$ mice died in utero. To test if there is leakiness into the hematopoietic compartment, I prepared DNA from blood and mammary tissues of three $c\text{-myb}/\text{MMTVcre}$ mice with various genotypes and performed Southern blot analysis (Figure 1). As seen in figure 1, There is leakiness into the blood and mammary tissues.




Figure 1: Southern Blot analysis showing leakiness into the blood and mammary tissues of $c\text{-myb}^{F/wt}/\text{MMTVcre}+$ mouse but no leakiness into the blood of $c\text{-myb}^{F/wt}/\text{WAPcre}+$ mouse.

To date, I have obtained a total of 79 c-myb/MMTVcre from 10 F2-litters. Figure 2 shows that I have one female breast-specific c-myb KO mouse, #2332 c-myb^{F/F}/MMTVcre+. Interestingly, #2332 displayed some sign of leakiness even in tail tissue. Apparently, the leakiness is not severe enough to cause lethality. A possibility as to why I did not obtain any c-myb^{F/F}/MMTVcre- mice may be a lower chance of obtaining these mice since both dam and sire are MMTVcre positive.




Figure 2: Southern Blot analysis on mouse tail DNA indicating the procurement of a breast-specific c-myb KO female mouse, #2332 c-myb^{F/F}/MMTVcre+.

In addition to the MMTV mouse model, I have generated another breast-specific c-myb KO mouse model using WAPcre mice. So far, I have only one F2 c-myb/WAPcre litter with 7 pups. Figure 3 indicates that I have 3 c-myb^{F/F}/WAPcre mice, #2552, #2553 and #2554. #2551 is a female that is negative for the WAPcre transgene. #2553 is a male that carries the WAPcre transgene. #2554 is WAPcre positive and is another breast-specific c-myb KO mouse model.




Figure 3: Southern blot analysis of mouse tail DNA from F2 c-myb/WAPcre pups.

Key Research Accomplishments

- Production of 7 karyotypically normal type II conditional c-myb deletion ES cell clones.
- Creation of c-myb floxed mice.
- Generation of breast-specific c-myb KO mouse models:

-c-myb^{F/F}/MMTVcre+

- c-myb^{F/F}/WAPcre+.

Reportable Outcomes

None

Conclusions

I have generate c-myb floxed (c-myb^F) mice which will be an important model not only for breast development and breast cancer but also for examining the role c-myb in the normal development and cancer progression of other tissues as well, such as blood, colon and brain. By generating two breast-specific KO mouse models, I have completed the major goal of my original grant proposal. We believe these breast-specific c-myb conditional knockout mice will provide two invaluable models for dissecting the role of c-myb in normal development as well as gain insight into the role of its aberrant expression in breast cancer. Furthermore, we believe that a detailed molecular understanding of how c-myb contributes to tumor progression is of major importance for future therapy.

References

1. Cline MJ, Battifora H, Yokota J. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol. 1987 Jul;5(7):999-1006.

2. Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. *Oncogene*. 1990 Jan;5(1):131-5.
3. Gudas JM, Klein RC, Oka M, Cowan KH. Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. *Clin Cancer Res*. 1995 Feb;1(2):235-43.
4. Biunno I, Pozzi MR, Pierotti MA, Pilotti S, Cattoretti G, Della Porta G. Structure and expression of oncogenes in surgical specimens of human breast carcinomas. *Br J Cancer*. 1988 May;57(5):464-8.
5. Zhou DJ, Ahuja H, Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. *Oncogene*. 1989 Jan;4(1):105-8.
6. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J, Borg A. MYB oncogene amplification in hereditary BRCA1 breast cancer. *Cancer Res*. 2000 Oct 1;60(19):5323-8.
7. Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ and Ishii S. Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. *Proc Natl Acad Sci U S A*. 1989 Aug;86(15):5758-62.
8. Weston K and Bishop JM. Transcriptional Activation by the V-myb Oncogene and Its Cellular Progenitor, c-myb. *Cell* 1989 58: 85.
9. Golay J., Capucci A, Arsura M, Castellano M, Rizzo V, Introna M. Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. *Blood*. 1991 Jan 1;77(1):149-58.
10. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott WJ Jr, Potter SS. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. *Cell*. 1991 May 17;65(4):677-89.
11. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, Hennighausen L. Cre-mediated gene deletion in the mammary gland. *Nucleic Acids Res*. 1997 Nov 1;25(21):4323-30.